(Reuters) – AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in patients with breast cancer in a late stage trial, the British drugmaker said on Thursday.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
AstraZeneca’s Lynparza reduces relapse and death in breast cancer patients
Jun 3, 2021 | 5:24 PM
